Liquidia Settles All Litigation With United Therapeutics for $380.7M, Securing YUTREPIA's Future
LQDA sits 45% above its 52-week low of $21.94.
Summary
Liquidia has reached a global settlement with United Therapeutics, resolving all six pending lawsuits and removing the existential threat to YUTREPIA's commercialization in PAH. The company will pay a net $380.7 million in installments across 2026 and 2027, with $175 million due within 30 business days, and two $72.7 million installments due by January 31 and April 30, 2027. Liquidia shares jumped 42% after the settlement, and the company will pay $60.3 million this month to antitrust parties. As part of the deal, Liquidia terminates its promotional agreement for treprostinil injection and removes the PH-ILD indication from YUTREPIA's label, ceasing promotion for that use. Liquidia agreed not to appeal the September 30 court ruling that found two United Therapeutics patents valid and infringed, which had sent Liquidia shares down 25% in one day and another 14.6% the next. The settlement eliminates the overhang of potential injunctions or damages that could have halted YUTREPIA sales, which generated $170.4 million in Q2 2026 and preliminary Q3 sales of $222.7 million. While the $380.7 million payment is substantial, it is manageable relative to Liquidia's $2.4 billion market cap and preserves the core PAH franchise.
Updated with a Seeking Alpha report · What changed
Updates
· Seeking Alpha — Liquidia shares jumped 42% after the settlement; it will pay $60.3M this month to antitrust parties and reported preliminary Q3 YUTREPIA sales of $222.7M.
- Two $72.7 million installments are due by January 31 and April 30, 2027.
- Liquidia agreed not to appeal the September 30 court ruling.
· SEC 8-K — The 8-K details related-party agreements: $21.75M to Sandoz, $19.05M to Henderson, $19.45M to PBM, and a Seventh Amendment increasing minimum cash covenant from $15M to $45M.
At the time of this announcement, LQDA was trading at $31.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $21.94 to $93.61. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.